Evaluation of the use of high-dose cytoreduction with autologous marrow rescue in various malignancies.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001388:Aziridines / Q000008:administration & dosage; D016227:Benzoquinones; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000473:pathology / Q000628:therapy; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D009447:Neuroblastoma / Q000188:drug therapy; D014182:Transplantation, Autologous
D001388:Aziridines; D016227:Benzoquinones; C029108:diaziquone